PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28248681
OWN - NLM
STAT- MEDLINE
DA  - 20170301
DCOM- 20170315
LR  - 20170315
IS  - 1972-2680 (Electronic)
IS  - 1972-2680 (Linking)
VI  - 11
IP  - 2
DP  - 2017 Feb 28
TI  - Risk factors for infection development after transrectal prostate biopsy and the 
      role of resistant bacteria in colonic flora.
PG  - 188-191
LID - 10.3855/jidc.7067 [doi]
AB  - INTRODUCTION: In this study, we aimed to identify risk factors for the
      development of infectious complications after prostate biopsy and to investigate 
      the role of intestinal colonization of bacteria that are resistant to
      prophylactic antibiotics. METHODOLOGY: A total of 168 patients who had undergone 
      transrectal prostate biopsy (TRPB) under ciprofloxacin and gentamycin prophylaxis
      were included in the study. Stool cultures and subsequent antibiotic
      susceptibility testing were performed in all patients before the start of
      antibiotic prophylaxis. RESULTS: Of the 168 patients, 17 (10.1%) developed
      urinary tract infection (UTI), while 6 (3.57%) developed sepsis within seven days
      after biopsy. Ciprofloxacin-resistant bacterial colonization was detected in 81
      (48.2%) of the patients. None of the patients with ciprofloxacin-sensitive
      bacteria in intestinal flora developed a UTI. The colonization of intestinal
      ciprofloxacin-resistant bacteria increased UTI risk significantly after TRPB (p <
      0.0001). Urolithiasis history, presence of permanent urinary catheterization,
      hospitalization history for more than 48 hours in the last year, and recent
      antibiotic usage significantly increased UTI risk after TRPB. CONCLUSIONS:
      Development of an infection was more frequent in patients with resistant
      bacterial colonization. We hope to guide more comprehensive studies designed to
      find a standard prophylactic regimen for TRPB that can be used all over the
      world.
FAU - Eruz, Emine Dilek
AU  - Eruz ED
AD  - Faculty of Medicine, Ankara University, Ankara, Turkey.
      [email protected]
FAU - Yalci, Aysun
AU  - Yalci A
FAU - Ozden, Eriz
AU  - Ozden E
FAU - Aslaner, Halide
AU  - Aslaner H
FAU - Ogucu-Durgun, Suna
AU  - Ogucu-Durgun S
FAU - Koseoglu-Taymur, Deniz Derya
AU  - Koseoglu-Taymur DD
FAU - Memikoglu, Kemal Osman
AU  - Memikoglu KO
FAU - Erdem, Hakan
AU  - Erdem H
FAU - Kurt, Halil
AU  - Kurt H
LA  - eng
PT  - Journal Article
DEP - 20170228
PL  - Italy
TA  - J Infect Dev Ctries
JT  - Journal of infection in developing countries
JID - 101305410
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Gentamicins)
RN  - 5E8K9I0O4U (Ciprofloxacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/administration & dosage
MH  - Antibiotic Prophylaxis/methods
MH  - Bacteria/*drug effects/isolation & purification
MH  - Bacterial Infections/*epidemiology
MH  - Biopsy/*adverse effects
MH  - Ciprofloxacin/administration & dosage
MH  - Colon/*microbiology
MH  - *Drug Resistance, Bacterial
MH  - Feces/microbiology
MH  - Gentamicins/administration & dosage
MH  - Humans
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Middle Aged
MH  - Preoperative Care/methods
MH  - Prospective Studies
MH  - Prostatic Diseases/*diagnosis
MH  - Risk Factors
EDAT- 2017/03/02 06:00
MHDA- 2017/03/16 06:00
CRDT- 2017/03/02 06:00
PHST- 2015/04/27 [received]
PHST- 2015/08/21 [accepted]
PHST- 2017/01/05 [revised]
PST - epublish
SO  - J Infect Dev Ctries. 2017 Feb 28;11(2):188-191. doi: 10.3855/jidc.7067.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>